Provectus Biopharmaceuticals, Inc.
PVCT
$0.07
$0.0112.01%
OTC PK
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -79.36% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -79.36% | |||
| Cost of Revenue | -62.37% | 125.61% | |||
| Gross Profit | 59.67% | -685.69% | |||
| SG&A Expenses | -4.93% | -0.08% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -32.61% | 38.04% | |||
| Operating Income | 30.30% | -71.52% | |||
| Income Before Tax | 28.54% | -59.44% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 28.54% | -59.44% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -67.37% | 75.35% | |||
| Net Income | 27.73% | -59.14% | |||
| EBIT | 30.30% | -71.52% | |||
| EBITDA | 30.30% | -71.54% | |||
| EPS Basic | 27.91% | -59.26% | |||
| Normalized Basic EPS | 28.00% | -66.67% | |||
| EPS Diluted | 27.91% | -59.26% | |||
| Normalized Diluted EPS | 28.00% | -66.67% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||